| abstract |
The present invention relates to agents that reduce the activity of GDF15, and in particular to the use of such agents to treat or prevent diseases associated with high or undesirable levels of GDF15. The present invention is based on the discovery that GDF15 binds to its receptors CLPTM1 and QRFPR, in the form of a binder that can bind to the receptor and inhibit the interaction between GDF15 and the receptor, A medicament for such use is provided. In addition, the agent includes a polypeptide derived from a receptor that can bind to GDF15 and inhibit the effect of GDF15 on the receptor. Also provided are diagnostic methods based on detecting the interaction, or the effect of the interaction, and cytotoxic immune cells modified to reduce CLPTM1 levels and / or CLPTM1 activity. |